SCHEMBL5652419

SCHEMBL5652419

Cc1cccc2[nH]c(-c3ccc(C(=O)NCCCN)cc3)nc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPSE Q9Y251 3/20 0.57
KDM4E B2RXH2 2/20 0.56
NPC1 O15118 2/20 0.56
ALDH1A1 P00352 2/20 0.56
TP53 P04637 2/20 0.56
HPGD P15428 2/20 0.56
RAB9A P51151 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
HSD17B10 Q99714 2/20 0.56
MGAM O43451 6/20 0.54
GAA P10253 6/20 0.54
SI P14410 6/20 0.54
MGAM2 Q2M2H8 6/20 0.54
MAPK8 P45983 1/20 0.53
MAPT P10636 1/20 0.51
VSIR Q9H7M9 1/20 0.49
PARP1 P09874 2/20 0.47
FLT3 P36888 2/20 0.47
RAD52 P43351 1/20 0.45
UHRF1 Q96T88 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5649682 0.88 MAPK8 (0.54) KDM4EHSD17B10MAPK8PARP1FLT3
SCHEMBL5652087 0.86 FLT3 (0.49) HPSEKDM4ENPC1ALDH1A1TP53
SCHEMBL5649050 0.85 HPSE (0.53) HPSEKDM4ENPC1ALDH1A1TP53
SCHEMBL5650962 0.85 MGAM (0.51) HPSEKDM4EHSD17B10MGAMGAA
SCHEMBL5650424 0.84 HPSE (0.50) HPSEKDM4ENPC1ALDH1A1TP53
SCHEMBL5652427 0.83 MAPK8 (0.47) HPSEMAPK8FLT3
SCHEMBL5649719 0.82 MGAM (0.48) HPSEMGAMGAASIMGAM2
SCHEMBL5648974 0.81 KDM4E (0.53) KDM4EALDH1A1HPGDSMN1; SMN2PARP1
SCHEMBL6585826 0.81 HPSE (0.67) HPSEKDM4ENPC1ALDH1A1TP53
SCHEMBL5648785 0.81 HPSE (0.53) HPSEKDM4ESMN1; SMN2HSD17B10MGAM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 HPSE 3728/4885KDM4E 1605/4885NPC1 1699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.